Rosenblatt Re-Rates Imax As Jurassic World Dominion Continues To Rule Charts

Rosenblatt analyst Steve Frankel reiterated a Buy rating on Imax Corp IMAX with a price target of $25.

Jurassic World Dominion raked $58.7 million in its second weekend, beating Lightyear to lead the domestic box office. 

To date, Dominion has earned $259 million. With a three-day opening of $51 million, Lightyear missed industry expectations of $70 million - $85 million. 

Top Gun: Maverick added $44 million to push its domestic total to $461 million. Overseas, Lightyear grossed a disappointing $34.6 million from 43 markets. 

Meanwhile, Jurassic World: Dominion added another $76.1 million to bring its international total to $372.4 million ($622.2 million globally), owning the winner's mantle in China, earning $92.8 million so far.

Top Gun: Maverick earned $39.7 million, bringing the international total to $419 million and $885 million globally, making it Tom Cruise's best-selling film.

IMAX dedicated most of its domestic capacity to Dominion, except for matinee showings of Lightyear. As a result, Imax accounted for 8% of Dominion's weekend for $4.6 million in GBO, bringing the film's domestic total to $20.5 million. 

Overseas, Dominion generated another $4.2 million in GBO, bringing the international GBO total to $20.9 million, including $9.9 million from China.

Lightyear added $1.7 million in GBO, with $1.1 million coming from domestic screens, and Top Gun: Maverick generated $2.1 million in international GBO to bring the film's global total to $79 million.

Price Action: IMAX shares traded higher by 1.6% at $15.21 on the last check Tuesday.

Photo via Wikimedia Commons

IMAX Logo
IMAXImax Corp
$28.44-2.60%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
91.63
Growth
50.58
Quality
Not Available
Value
46.46
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Comments
Loading...